

Attorney Docket No.: A-64260-2/RMS/AMS

<u>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</u>

In re application of

NOLAN, Garry P.

Serial No. 08/963,368

Filed: November 3, 1997

For: METHODS FOR SCREENING

FOR TRANSDOMINANT

INTRACEI LULAR EFFECTOR

PEPTIDES AND RNA

MOLECUIES

Examiner: VANDERVEGT, F.

Group Art Unit: 1644

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patenta, BOX RCE, Washington, DC

20231 on:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AND STATEMENT OF RELATEDNESS

Commissioner for Patents BOX RCE Washington, DC 20231

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trailemark Office to the References cited on the accompanying form PTO-1449. Since copies of these references were provided either by Applicant or Examiner in 08/789,333, filed January 23, 1997 (now U.S. Pat. No. 6,153,380); 08/787,738, filed January 23, 1997; 08/589,109, filed January 23, 1996; or 08/589,911, filed January 23, 1996, upon

Serial No.: 08/963,368
Filed: November 3, 1997

which the instant application relies for its priority date, in accordance with 37 C.F.R. §1.98(d), no copies of these references are enclosed with this document.

None of the foregoing references is believed to disclose the invention as claimed.

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall he inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

Applicants submit that an opposition has recently been filed in Australia, several of the references cited here n are from that opposition, and further documents may be forthcoming.

Applicants further submit that references 35, 38, and 41-43 are in German and were cited in an opposition in Europe against EP 0 832 207 B1, of which the PCT equivalent, WO 96/38553, has been previously cited by Applicants or the Examiner. English equivalents of references 41-43 were provided as described above. Further documents may be forthcoming.

Applicants also wish to draw the attention of the Patent Office to the related U.S. applications, serial number 09/727,715, filed November 28, 2000; serial number 09/919,635, filed July 31, 2001; serial number 09/918,601, filed July 30, 2001; and serial number 09/916,940, filed July 27, 2001; all of which are now pending.

This Information Disclosure Statement is accompanied by a Request for Continued Examination pursuant to 37 C.F.R. §1.114 and the requisite fee as set forth in 37 C.F.R. §1.17(e). The Commissioner is authorized to charge any additional fees which may be

Serial No.: 08/963,368 Filed: November 3, 1997

required, or credit an / overpayment to Deposit Account No. 06-1300 (Our Order No.

A-64260-2/RMS/ANS).

Respectfully submitted,

FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT

Dated: Suplember: 17, 2001

Robin M. Silvie Reg. No. 38,304

Four Embarcadero Center Suite 3400 San Francisco, CA 94111-4187 Telephone: (415) 781-1989